Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis.

Huiyi LiuLu FuShuyu JinXingdong YeYanlin ChenSijia PuYumei Xue

Published in: Cancer innovation (2024)

Our findings suggest that the incidence rate of all cardiovascular toxicity and severe cardiovascular toxicity increased in patients who were administered CTLA-4 inhibitors. In addition, the risk of serious cardiovascular toxic events was independent of the type of adverse event. From these results, physicians should assess the benefits and risks of CTLA-4 inhibitors when treating malignancies.

Keyphrases

oxidative stress
primary care
risk factors
early onset
risk assessment
human health
oxide nanoparticles